Swiss National Bank’s Regeneron Pharmaceuticals REGN Stock Holding History

Swiss National Bank’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$234M	Buy	303,140 +17,680	+6%	+$13.5M	0.13%	123
2025 Q4	$220M	Sell	285,460 -20,540	-7%	-$13.9M	0.13%	114
2025 Q3	$172M	Sell	306,000 -17,700	-5%	-$10M	0.1%	167
2025 Q2	$170M	Buy	323,700 +18,900	+6%	+$10.5M	0.1%	169
2025 Q1	$193M	Sell	304,800 -1,500	-0.5%	-$1.03M	0.14%	126
2024 Q4	$218M	Sell	306,300 -15,300	-5%	-$12.8M	0.15%	113
2024 Q3	$338M	Buy	321,600 +2,000	+0.6%	+$2.23M	0.22%	74
2024 Q2	$336M	Sell	319,600 -1,200	-0.4%	-$1.16M	0.23%	72
2024 Q1	$309M	Sell	320,800 -13,000	-4%	-$12.4M	0.22%	82
2023 Q4	$293M	Sell	333,800 -13,300	-4%	-$11M	0.22%	85
2023 Q3	$286M	Sell	347,100 -41,200	-11%	-$32.4M	0.22%	80
2023 Q2	$279M	Sell	388,300 -36,700	-9%	-$28.3M	0.19%	97
2023 Q1	$349M	Sell	425,000 -10,600	-2%	-$7.99M	0.24%	79
2022 Q4	$314M	Sell	435,600 -32,572	-7%	-$24M	0.23%	88
2022 Q3	$323M	Buy	468,172 +5,300	+1%	+$3.34M	0.23%	76
2022 Q2	$274M	Buy	462,872 +5,000	+1%	+$3.25M	0.19%	102
2022 Q1	$320M	Buy	457,872 +58,400	+15%	+$36.9M	0.18%	98
2021 Q4	$252M	Sell	399,472 -14,500	-4%	-$8.92M	0.15%	116
2021 Q3	$251M	Sell	413,972 -15,400	-4%	-$9.56M	0.16%	112
2021 Q2	$240M	Sell	429,372 -177,450	-29%	-$89.9M	0.15%	124
2021 Q1	$287M	Buy	606,822 +10,700	+2%	+$5.21M	0.19%	103
2020 Q4	$288M	Buy	596,122 +26,000	+5%	+$14M	0.2%	101
2020 Q3	$319M	Buy	570,122 +90,500	+19%	+$54.9M	0.25%	76
2020 Q2	$299M	Buy	479,622 +165,400	+53%	+$93.9M	0.25%	75
2020 Q1	$153M	Buy	314,222 +58,800	+23%	+$24.3M	0.16%	131
2019 Q4	$95.9M	Sell	255,422 -11,400	-4%	-$3.84M	0.1%	210
2019 Q3	$74M	Buy	266,822 +4,422	+2%	+$1.31M	0.08%	262
2019 Q2	$82.1M	Sell	262,400 -3,800	-1%	-$1.27M	0.09%	240
2019 Q1	$109M	Buy	266,200 +7,400	+3%	+$3.05M	0.12%	185
2018 Q4	$96.7M	Buy	258,800 +5,100	+2%	+$1.87M	0.12%	178
2018 Q3	$103M	Sell	253,700 -8,100	-3%	-$3.08M	0.11%	190
2018 Q2	$90.3M	Buy	261,800 +7,900	+3%	+$2.47M	0.1%	209
2018 Q1	$87.4M	Sell	253,900 -35,000	-12%	-$12.2M	0.11%	207
2017 Q4	$109M	Buy	288,900 +400	+0.1%	+$162K	0.12%	184
2017 Q3	$129M	Buy	288,500 +3,100	+1%	+$1.48M	0.15%	152
2017 Q2	$140M	Buy	285,400 +10,100	+4%	+$4.42M	0.17%	137
2017 Q1	$107M	Buy	275,300 +59,300	+27%	+$22M	0.13%	174
2016 Q4	$79.3M	Buy	216,000 +1,700	+0.8%	+$646K	0.13%	184
2016 Q3	$86.2M	Sell	214,300 -2,100	-1%	-$842K	0.14%	162
2016 Q2	$75.6M	Buy	216,400 +17,300	+9%	+$6.66M	0.12%	187
2016 Q1	$68.8M	Buy	199,100 +60,600	+44%	+$25M	0.13%	178
2015 Q4	$75.2M	Buy	138,500 +2,900	+2%	+$1.57M	0.18%	123
2015 Q3	$63.1M	Buy	135,600 +13,800	+11%	+$7.41M	0.16%	143
2015 Q2	$62.1M	Buy	121,800 +300	+0.2%	+$146K	0.16%	146
2015 Q1	$54.9M	Buy	121,500 +48,000	+65%	+$20.3M	0.15%	161
2014 Q4	$30.2M	Sell	73,500 -2,100	-3%	-$826K	0.11%	197
2014 Q3	$27.3M	Sell	75,600 -700	-0.9%	-$235K	0.1%	212
2014 Q2	$21.6M	Buy	76,300 +800	+1%	+$237K	0.08%	266
2014 Q1	$22.7M	Sell	75,500 -6,900	-8%	-$2.13M	0.09%	240
2013 Q4	$22.7M	Sell	82,400 -700	-0.8%	-$201K	0.09%	245
2013 Q3	$26M	Buy	83,100 +1,900	+2%	+$500K	0.11%	219
2013 Q2	$18.3M	Buy	+81,200	New	+$18.9M	0.08%	264

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Swiss National Bank's REGN Position: Q1 2026 in Review

Swiss National Bank increased its Regeneron Pharmaceuticals (REGN) stake by 6.2% in Q1 2026, buying an estimated $13.5M and bringing the position to 303,140 shares worth $234M. The position accounts for 0.13% of the portfolio, ranked #123.

Swiss National Bank first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $349M in Q1 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Swiss National Bank held 303,140 shares of Regeneron Pharmaceuticals worth $234M as of Q1 2026.
Swiss National Bank bought 17,680 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $13.5M.
Regeneron Pharmaceuticals made up 0.13% of Swiss National Bank's portfolio in Q1 2026, its #123 holding.
Swiss National Bank first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Swiss National Bank's Regeneron Pharmaceuticals position peaked at $349M in Q1 2023.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.